Citations

Clear

2413 citation(s) found for "Yu, Jason W".

Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales
Tay, Jason , Vij, Ravi , Norkin, Maxim , Kindwall‐Keller, Tamila L. , Roberts, Jenna , White, Darrell , Wood, Robert , Blanthorn-Hazell, Sophee , Rossi, Adriana , Dhanasiri, Sujith, Zafar, Faiza , Newhouse, Kim, McCurdy, Arleigh , Buadi, Francis K. , Rossi, Adriana , McCurdy, Arleigh

Mayo Clinic

Leukemia & Lymphoma | October 31, 2018 | Volume: 60 | Issue: 5 | Pages: 1275-1282

10.1080/10428194.2018.1523399 | PMID 30380358 Get It

The MIST Guidelines: The Lumbar Spinal Stenosis Consensus Group Guidelines for Minimally Invasive Spine Treatment
Grider, Jay S., Pope, Jason E. , Falowski, Steven , Lamer, Tim J. , Calodney, Aaron , Lee, Eric , Wahezi, Sayed , Hunter, Corey , Benyamin, Rasmin, Chopko, Bohdan W., Demesmin, Didier, Diwan, Sudhir , Gharibo, Christopher, Kapural, Leo, Kloth, David, Klagges, Brian D., Harned, Michael , Simopoulos, Tom, McJunkin, Tory , Carlson, Jonathan D. , Rosenquist, Richard W. , Lubenow, Timothy R. , Deer, Timothy R. , Grider, Jay S. , Provenzano, David , Sayed, Dawood , Kim, Chong Ae , Gupta, Mayank , Mekhail, Nagy

Mayo Clinic

Pain Practice | October 28, 2018 | Volume: 19 | Issue: 3 | Pages: 250-274

10.1111/papr.12744 | PMID 30369003 Get It

Abstract Background Lumbar spinal stenosis ( LSS ) can lead to compression of neural elements and manifest as low back and leg pain. LSS has traditionally been treated with a variety of conservative (pain medications, physical therapy, epidural spinal injections) and invasive (surgical decompression) options. Recently, several minimally invasive procedures have expanded the treatment options. Methods The Lumbar Spinal Stenosis Consensus Group convened to evaluate the peer‐reviewed literature as the basis for making minimally invasive spine treatment ( MIST ) recommendations. Eleven consensus points were clearly defined with evidence strength, recommendation grade, and consensus level using U.S. Preventive Services Task Force criteria. The Consensus Group also created a treatment algorithm. Literature searches yielded 9 studies (2 randomized controlled trials [ RCT s]; 7 observational studies, 4 prospective and 3 retrospective) of minimally invasive spine treatments, and 1 RCT for spacers. Results The LSS treatment choice is dependent on the degree of stenosis; spinal or anatomic level; architecture of the stenosis; severity of the symptoms; failed, past, less invasive treatments; previous fusions or other open surgical approaches; and patient comorbidities. There is Level I evidence for percutaneous image‐guided lumbar decompression as superior to lumbar epidural steroid injection, and 1 RCT supported spacer use in a noninferiority study comparing 2 spacer products currently available. Conclusions MISTs should be used in a judicious and algorithmic fashion to treat LSS , based on the evidence of efficacy and safety in the peer‐reviewed literature. The MIST Consensus Group recommend that these procedures be used in a multimodal fashion as part of an evidence‐based decision algorithm.
P4‐288: DETAILS OF THE NEW ALZHEIMER'S ASSOCIATION BEST CLINICAL PRACTICE GUIDELINES FOR THE EVALUATION OF NEURODEGENERATIVE COGNITIVE BEHAVIORAL SYNDROMES, ALZHEIMER'S DISEASE AND DEMENTIAS IN THE UNITED STATES
Norman, Mary S., Karlawish, Jason , Sano, Mary , Onyike, Chiadi U. , Lin, Paige E. , Clevenger, Carolyn , Scanland, Susan, Hendrix, James A. , Dickerson, Brad C., Atri, Alireza , Knopman, David S. , Norman, Mary, Lin, Paige, Carrillo, María C.

Mayo Clinic

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_30 | Pages: No page available

10.1016/j.jalz.2018.07.110 Get It

O3‐06‐02: POLYGENIC SCORE ANALYSIS OF EXONIC VARIANTS IN AN IMMUNE CO‐REGULATORY NETWORK IDENTIFIES NOVEL PROTEIN‐ALTERING VARIANTS THAT ASSOCIATE WITH ALZHEIMER'S DISEASE
Reddy, Joseph S. , Allen, Mariet , Wang, Xue , Gregory, Jenkins D., Toral, Shastri M., Sarangi, Vivekananda , Asmann, Yan W. , Carrasquillo, Minerva M. , Ren, Yingxue , Younkin, Curtis, Rademakers, Rosa , Ertekin‐Taner, Nilüfer , Younkin, Steven G. , Biernacka, Joanna M. , McDonnell, Shannon K. , Sinnwell, Jason P. , Carrasquillo, Minerva M. , Pottier, Cyril , Ross, Owen A.

Mayo Clinic

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_19 | Pages: No page available

10.1016/j.jalz.2018.06.2801 Get It

O1‐02‐03: DIAN‐TU ADAPTIVE PREVENTION TRIAL LAUNCH AND BASELINE DATA
Santacruz, Anna , Farlow, Martin R. , Salloway, Stephen , Fagan, Anne M. , Wang, Guoqiao , Koeppe, Bob, Martényi, Ferenc, Yaari, R. , Siemers, Eric , Clifford, David B. , Bateman, Randall J. , Mills, Susan, Morris, John C. , Benzinger, Tammie L.S. , Goate, Alison , Hassenstab, Jason , Xiong, Chengjie , Jack, Clifford R. , Searle, Alison, McDade, Eric

Mayo Clinic

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_3 | Pages: No page available

10.1016/j.jalz.2018.06.2338 Get It

P3‐178: THE PRESENCE OF NEURONAL PROTEINS IN HUMAN SUBMANDIBULAR GLAND IN ALZHEIMER'S DISEASE AND NONDEMENTED INDIVIDUALS
Young, Zapporah T. , Sabbagh, Marwan N. , Sue, Lucia I., Beach, Thomas G. , Gestwicki, Jason E. , Armas, Cristina, Serrano, Geidy E. , Adler, Charles H. , Grinberg, Lea T. , Dugger, Brittany N.

Mayo Clinic

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_21 | Pages: No page available

10.1016/j.jalz.2018.06.1536 Get It

Cosmetic outcomes and quality of life in children with cardiac implantable electronic devices
Gist, Katja M. , Marino, Bradley S. , Palmer, Claire , Fish, Frank A. , Moore, Jeremy P. , Czosek, Richard J. , Cassedy, Amy , Law, Ian H. , Garnreiter, Jason M., Cannon, Bryan C. , Collins, Kathryn K. , Cannon, Bryan C , Law, Ian H , LaPage, Martin J

Mayo Clinic

Pacing and Clinical Electrophysiology | October 18, 2018 | Volume: 42 | Issue: 1 | Pages: 46-57

10.1111/pace.13522 | PMID 30334588 Get It

AbstractBackgroundAxillary implant location is an alternative implant location in patients for cardiac implantable electronic devices (CIEDs) for the purposes of improved cosmetic outcome. The impact from the patient's perspective is unknown. The purpose of this study was to compare scar perception scores and quality of life (QOL) in pediatric patients with axillary CIED implant location versus the standard infraclavicular approach.MethodsThis is a multicenter prospective study conducted at eight pediatric centers and it includes patients aged from 8 to 18 years with a CIED. Patients with prior sternotomy were excluded. Scar perception and QOL outcomes were compared between the infraclavicular and axillary implant locations.ResultsA total of 141 patients (83 implantable cardioverter defibrillator [ICD]/58 pacemakers) were included, 55 with an axillary device and 86 with an infraclavicular device. Patients with an ICD in the axillary position had better perception of scar appearance and consciousness. Patients in the axillary group reported, on average, a total Pediatric QOL Inventory score that was 6 (1, 11) units higher than the infraclavicular group, after adjusting for sex and race (P = 0.02).ConclusionsQOL is significantly improved in axillary in comparison to the infraclavicular CIED position, regardless of device type. Scar perception is improved in patients with ICD in the axillary position.
PANOPLY: Omics-Guided Drug Prioritization Method Tailored to an Individual Patient
Sinnwell, Jason P. , Yu, Jia , Vedell, Peter T. , Weinshilboum, Richard M. , Wang, Liewei , Goetz, Matthew P. , Thompson, Kevin J. , Ingle, James N. , Suman, Vera, Sinnwell, Jason P , Kalari, Krishna R. , Tang, Xiaojia , Carlson, Erin E. , Weinshilboum, Richard M. , Boughey, Judy C. , Goetz, Matthew P. , Suman, Vera J.

Mayo Clinic

JCO Clinical Cancer Informatics | October 15, 2018 | Volume: No volume available | Issue: 2 | Pages: 1-11

10.1200/cci.18.00012 | PMID 30652605 Get It

Purpose The majority of patients with cancer receive treatments that are minimally informed by omics data. We propose a precision medicine computational framework, PANOPLY (Precision Cancer Genomic Report: Single Sample Inventory), to identify and prioritize drug targets and cancer therapy regimens. Materials and Methods The PANOPLY approach integrates clinical data with germline and somatic features obtained from multiomics platforms and applies machine learning and network analysis approaches in the context of the individual patient and matched controls. The PANOPLY workflow uses the following four steps: selection of matched controls to the patient of interest; identification of patient-specific genomic events; identification of suitable drugs using the driver-gene network and random forest analyses; and provision of an integrated multiomics case report of the patient with prioritization of anticancer drugs. Results The PANOPLY workflow can be executed on a stand-alone virtual machine and is also available for download as an R package. We applied the method to an institutional breast cancer neoadjuvant chemotherapy study that collected clinical and genomic data as well as patient-derived xenografts to investigate the prioritization offered by PANOPLY. In a chemotherapy-resistant patient-derived xenograft model, we found that that the prioritized drug, olaparib, was more effective than placebo in treating the tumor ( P < .05). We also applied PANOPLY to in-house and publicly accessible multiomics tumor data sets with therapeutic response or survival data available. Conclusion PANOPLY shows promise as a means to prioritize drugs on the basis of clinical and multiomics data for an individual patient with cancer. Additional studies are needed to confirm this approach.
AMS‐800 Artificial urinary sphincter in female patients with stress urinary incontinence: A systematic review
Peyronnet, B. , O’Connor, Eabhann , Khavari, Rose , Capon, G. , Allué, Marta , Hascoët, J. , Νitti, Victor W. , Gamé, X. , Gilleran, Jason , Castro-Sader, L., Cornu, Jean‐Nicolas , Waltregny, David , Ahyai, Sascha , Chung, Eric , Elliott, Daniel S. , Fournier, Georges , Brucker, Benjamin M. , Peyronnet, Benoit , Cornu, Jean-Nicolas , Manunta, Andrea Fabio

Mayo Clinic

Neurourology and Urodynamics | October 9, 2018 | Volume: 38 | Issue: S4 | Pages: No page available

10.1002/nau.23833 | PMID 30298943 Get It

Aims To perform a systematic review of studies reporting the outcomes of AMS‐800 artificial urinary sphincter (AUS) implantation in female patients with stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD). Methods A systematic literature search of the Medline and Embase databases was performed in June 2018 in accordance with the PRISMA statement. No time limit was used. The protocol was registered in PROSPERO (CRD42018099612). Study selection and data extraction were performed by two independent reviewers. Results Of 886 records screened, 17 were included. All were retrospective or prospective non‐comparative case series. One study reported on vaginal AUS implantation, 11 on open AUS implantation, two on laparoscopic AUS implantation, two on robot‐assisted AUS implantation and one compared open and robot‐assisted implantations. The vast majority of patients had undergone at least one anti‐incontinence surgical procedure prior to AUS implantation (69.1‐100%). The intraoperative bladder neck injury rates ranged from 0% to 43.8% and the intraoperative vaginal injury rates ranged from 0 to 25%. After mean follow‐up periods ranging from 5 to 204 months, the complete continence rates ranged from 61.1% to 100%. The rates of explantation, erosion and mechanical failure varied from 0% to 45.3%, 0% to 22.2% and 0% to 44.1%, respectively. Conclusions AMS‐800 AUS can provide excellent functional outcomes in female patients with SUI resulting from ISD but at the cost of a relatively high morbidity. High level of evidence studies are needed to help better define the role of AUS in the female SUI armamentarium.
In‐hospital opioid consumption, but not pain intensity scores, predicts 6‐month levels of pain catastrophizing following hepatic resection: A trajectory analysis
Pagé, M. Gabrielle , Karanicolas, Paul J. , Wei, Alice C. , McHardy, Paul , Ladak, Salima , Ayach, Nour, Sawyer, Jason , McCluskey, Stuart A. , Srinivas, Coimbatore, Katz, Joel , Coburn, Natalie G. , Hallet, Julie , Law, Calvin , Greig, Paul D., Clarke, Hance , Cleary, Sean, Cleary, Sean P.

Mayo Clinic

European Journal of Pain | October 9, 2018 | Volume: 23 | Issue: 3 | Pages: 503-514

10.1002/ejp.1324 | PMID 30298685 Get It

AbstractBackgroundThe study aims were to model acute pain intensity and opioid consumption trajectories up to 72 hr after open hepatic resection, identify predictors of trajectory membership and examine the association between trajectory memberships and 6‐month pain and psychological outcomes. This is a long‐term analysis of a published randomized controlled trial on the impact of medial open transversus abdominis plane catheters on post‐operative outcomes.MethodsA total of 152 patients (89 males; mean age 63.0 [range: 54–72]) completed questionnaires on pain and related characteristics pre‐operatively and 6 months post‐operatively. Total opioid use was recorded several times over a 72‐hr period while self‐reported pain intensity scores were collected multiple times until hospital discharge. Analyses were carried out using growth mixture modelling, logistic regression and general linear models.ResultsBoth pain intensity and opioid consumption showed that a four‐trajectory model best fits the data. Patients in the lowest opioid consumption trajectory were more likely to be classified in the constant mild pain intensity trajectory. Age and baseline levels of anxiety significantly predicted opioid trajectory membership while baseline depressive symptoms significantly predicted pain intensity trajectory membership. Patients in the two highest opioid consumption trajectories reported significantly higher levels of pain catastrophizing at 6 months compared to patients in the other 3 trajectories (all p < 0.05).ConclusionHigh consumption of opioids after surgery is associated with higher levels of pain catastrophizing 6 months later. Identification of patients within these trajectories may lead to the development of early interventions targeted to high risk individuals.SignificanceDifferences in initial levels of opioid consumption and rates of change in opioid consumption shortly after surgery can help predict long‐term psychological responses to pain. Identifying key characteristics associated with initial opioid consumption can lead to the development of cost‐effective early interventions targeted to high risk individuals.